The FDA's decision to place a clinical hold on Neumora Therapeutics' NMRA-266 study directly impacts the company's short-term stock performance. This regulatory action typically raises concerns among investors regarding the potential delay or modification of the study, which can affect the company's future revenue and growth prospects. The immediate negative reaction in the stock market reflects these concerns.